Email Alert | RSS

Journal of Peking University (Health Sciences) ›› 2020, Vol. 52 ›› Issue (4): 785-789. doi: 10.19723/j.issn.1671-167X.2020.04.034

Previous Articles     Next Articles

  

  • Received:2020-04-08 Online:2020-08-18 Published:2020-08-06

RICH HTML

   

PDF (PC)

CLC Number: 

  • R737.11

Figure 1

Homemade adjustable multi-channel Trocar"

Figure 2

Microwave ablation of renal tumor under real-time guidance of laparoscopic ultrasound"

Table 1

Overview of the patients’ data"

Patient
No.		 Age/
years		 Gender Side/tumor
number		 Comorbidities ASA
grade		 Number of
ablation
punctures		 Ablation
time/min		 Operation
time/min		 EBL
/mL		 Drainage
time/d		 Histopathology Follow-up/
months		 Local
efficacy
1 49 F Left/1 Schizophrenia Ⅱ 4 21 130 30 3 Hamartoma 65 CR
2 74 M Right/1 Renal insufficiency, CHD,
hypertension, mild cerebral
infarction, bilateral knee arthritis		 Ⅳ 4 20 105 20 4 Clear cell carcinoma 42 CR
3 68 M Right/1 COPD, hypertension Ⅲ 3 17 80 10 2 Papillary cell carcinoma 61 CR
4 56 F Right/1 Hypertension,
postoperative colon cancer		 Ⅲ 4 21 95 20 2 Clear cell carcinoma 60 CR
5 61 F Left/1 CHD, DM, hypertension Ⅲ 4 20 90 15 3 Clear cell carcinoma 52 CR
6 64 M Left/2 Renal insufficiency, DM,
COPD, tracheotomy for
laryngeal carcinoma		 Ⅳ 7 32 120 20 2 Clear cell carcinoma 41 CR
7 72 M Left/1 Mild cerebral infarction,
hypertension		 Ⅲ 5 28 116 30 3 Clear cell carcinoma 37 CR
8 84 M Left/1 Renal insufficiency,
hypertension, CHD		 Ⅳ 5 26 95 40 3 Clear cell carcinoma 33 CR
9 53 M Left/2 Renal insufficiency, solitary
kidney, VHL disease causes
lung metastasis		 Ⅲ 5 23 115 20 3 Clear cell carcinoma 29 CR
10 63 F Left/1 Hypertension, drug-induced
hepatic cirrhosis,
hepatic insufficiency		 Ⅲ 6 27 110 15 4 Hamartoma 27 PR

Table 2

R.E.N.A.L. nephrometry score of the tumors"

Patient No. (R)Radius (E)Exophytic (N)Nearness (A)Anterior/
posterior/x△		 (L)Location
score		 Total score+
Suffix “h”*
Score Maximal
diameter/cm		 Score Exophytic
properties/%		 Score Nearness to the
renal pelvis/mm
1 2 4.2 2 10% 3 1 a 3 10ah
2 2 4.5 2 30% 3 2 x 3 10xh
3 1 3.7 2 20% 2 6 a 2 7a
4 2 4.2 2 10% 2 6 x 2 8x
5 2 4.1 1 70% 2 5 p 2 7p
6 (2 tumors) 2 & 1 4.1 & 1.5 2 & 3 15% & 0% 3 & 1 4 & 20 x & a 3 & 1 10x & 6a
7 2 5.2 2 40% 3 3 a 3 10ah
8 2 5.3 1 55% 3 1 x 1 7xh
9 (2 tumors) 1 & 1 2 & 1.5 2 & 2 30% & 10% 1 & 1 21 & 16 a & p 1 & 2 5a & 6p
10 2 4.5 3 0% 3 2 p 3 11p

Figure 3

Patient 1, hamartoma of left kidney A, enhanced CT before ablation shows the anterior hamartoma is adjacent to the vessel of renal hilum; B, enhanced CT shows heterogeneous necrosis in the tumor after six months of surgery, and the ablation boundary of hamartoma is clearly visible."

Figure 4

Patient 2, clear cell carcinoma of right kidney A, enhanced MRI before ablation shows the tumor is located in the center of right kidney, which is adjacent to the renal hilum; B, enhanced CT shows completely necrosis in the tumor after six months of ablation, and there is no local enhancement in the tumor."

[1] Ljungberg B, Albiges L, Abu-Ghanem Y, et al. European Association of Urology Guidelines on renal cell carcinoma: The 2019 update[J]. Eur Urol, 2019,75(5):799-810.
[2] Chen W, Zheng R, Zeng H, et al. Annual report on status of cancer in China, 2011[J]. Chin J Cancer Res, 2015,27(1):2-12.
[3] Prins FM, Kerkmeijer LGW, Pronk AA, et al. Renal cell carcinoma: alternative nephron-sparing treatment options for small renal masses, a systematic review[J]. J Endourol, 2017,31(10):963-975.
[4] Kutikov A, Uzzo RG. The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth[J]. J Urol, 2009,182(3):844-853.
[5] Guan W, Bai J, Liu J, et al. Microwave ablation versus partial nephrectomy for small renal tumors: intermediate-term results[J]. J Surg Oncol, 2012,106(3):316-321.
[6] Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma[J]. Semin Liver Dis, 2010,30(1):52-60.
[7] Ficarra V, Novara G, Secco S, et al. Preoperative aspects and dimensions used for an anatomical (PADUA) classification of renal tumours in patients who are candidates for nephron-sparing surgery[J]. Eur Urol, 2009,56(5):786-793.
doi: 10.1016/j.eururo.2009.07.040 pmid: 19665284
[8] 范阳, 董隽, 祖强, 等. 机器人患肾切取、工作台手术联合机器人自体肾移植术在复杂肾肿瘤保留肾单位手术中的应用[J]. 中华泌尿外科杂志, 2019,40(5):340-345.
[9] Lieberman L, Barod R, Dalela D, et al. Use of main renal artery clamping predominates over minimal clamping techniques during robotic partial nephrectomy for complex tumors[J]. J Endourol, 2017,31(2):149-152.
pmid: 27936928
[10] Wagstaff P, Ingels A, Zondervan P, et al. Thermal ablation in renal cell carcinoma management: a comprehensive review[J]. Curr Opin Urol, 2014,24(5):474-482.
pmid: 25051022
[11] Katsanos K, Mailli L, Krokidis M, et al. Systematic review and meta-analysis of thermal ablation versus surgical nephrectomy for small renal tumours[J]. Cardiovasc Intervent Radiol, 2014,37(2):427-437.
[12] Zagoria RJ, Pettus JA, Rogers M, et al. Long-term outcomes after percutaneous radiofrequency ablation for renal cell carcinoma[J]. Urology, 2011,77(6):1393-1397.
pmid: 21492910
[13] Li X, Yu J, Liang P, et al. Combination therapy of three-dimensional (3D) visualisation operative treatment planning system and US-guided percutaneous microwave ablation in larger renal cell carcinomas (D >/= 4 cm): preliminary results[J]. Int J Hyperthermia, 2017,33(3):271-277.
[14] Motzer RJ, Jonasch E, Agarwal N, et al. Kidney cancer, version 2.2017, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2017,15(6):804-834.
[15] Lubner MG, Brace CL, Hinshaw JL, et al. Microwave tumor ablation: mechanism of action, clinical results, and devices[J]. J Vasc Interv Radiol, 2010,21(8 Suppl):192-203.
[16] Ong SL, Gravante G, Metcalfe MS, et al. Efficacy and safety of microwave ablation for primary and secondary liver malignancies: a systematic review[J]. Eur J Gastroenterol Hepatol, 2009,21(6):599-605.
[17] Abboud SE, Patel T, Soriano S, et al. Long-term clinical outcomes following radiofrequency and microwave ablation of renal cell carcinoma at a single VA medical center[J]. Curr Probl Diagn Radiol, 2018,47(2):98-102.
[18] Feng B, Liang P. Local thermal ablation of renal cell carcinoma[J]. Eur J Radiol, 2012,81(3):437-440.
pmid: 21239130
[19] Larcher A, Fossati N, Mistretta F, et al. Long-term oncologic outcomes of laparoscopic renal cryoablation as primary treatment for small renal masses[J]. Urol Oncol, 2015, 33(1): 22.e1-22.e9.
doi: 10.1016/j.urolonc.2014.09.013 pmid: 25443268
[20] Fazio LM, Downey D, Nguan CY, et al. Intraoperative laparoscopic renal ultrasonography: use in advanced laparoscopic renal surgery[J]. Urology, 2006,68(4):723-727.
doi: 10.1016/j.urology.2006.04.022 pmid: 17070341
[21] Castle SM, Salas N, Leveillee RJ. Initial experience using microwave ablation therapy for renal tumor treatment: 18-month follow-up[J]. Urology, 2011,77(4):792-797.
doi: 10.1016/j.urology.2010.12.028
[22] Uhlig J, Strauss A, Rucker G, et al. Partial nephrectomy versus ablative techniques for small renal masses: a systematic review and network meta-analysis[J]. Eur Radiol, 2019,29(3):1293-1307.
doi: 10.1007/s00330-018-5660-3 pmid: 30255245
[1] Zezhen ZHOU,Shaohui DENG,Ye YAN,Fan ZHANG,Yichang HAO,Liyuan GE,Hongxian ZHANG,Guoliang WANG,Shudong ZHANG. Predicting the 3-year tumor-specific survival in patients with T3a non-metastatic renal cell carcinoma [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 673-679.
[2] Jie YANG,Jieli FENG,Shudong ZHANG,Lulin MA,Qing ZHENG. Clinical effects of transesophageal echocardiography in different surgical methods for nephrectomy combined with Mayo Ⅲ-Ⅳ vena tumor thrombectomy [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 631-635.
[3] Fan SHU,Yichang HAO,Zhanyi ZHANG,Shaohui DENG,Hongxian ZHANG,Lei LIU,Guoliang WANG,Xiaojun TIAN,Lei ZHAO,Lulin MA,Shudong ZHANG. Functional and oncologic outcomes of partial nephrectomy for cystic renal cell carcinoma: A single-center retrospective study [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 667-672.
[4] Kewei CHEN,Shaohui DENG,Zhuo LIU,Hongxian ZHANG,Lulin MA,Shudong ZHANG. Discussion on the surgical timing of rupture and hemorrhage of renal angiomyolipoma [J]. Journal of Peking University (Health Sciences), 2024, 56(2): 326-331.
[5] Zi-xuan XUE,Shi-ying TANG,Min QIU,Cheng LIU,Xiao-jun TIAN,Min LU,Jing-han DONG,Lu-lin MA,Shu-dong ZHANG. Clinicopathologic features and prognosis of young renal tumors with tumor thrombus [J]. Journal of Peking University (Health Sciences), 2023, 55(5): 802-811.
[6] Min QIU,You-long ZONG,Bin-shuai WANG,Bin YANG,Chu-xiao XU,Zheng-hui SUN,Min LU,Lei ZHAO,Jian LU,Cheng LIU,Xiao-jun TIAN,Lu-lin MA. Treatment outcome of laparoscopic partial nephrectomy in patients with renal tumors of moderate to high complexity [J]. Journal of Peking University (Health Sciences), 2023, 55(5): 833-837.
[7] 聪 田,军 刘,波 杨,佳佳 乔,晓波 黄,清泉 许. [J]. Journal of Peking University (Health Sciences), 2023, 55(5): 948-952.
[8] Qi SHEN,Yi-xiao LIU,Qun HE. Mucinous tubular and spindle cell carcinoma of kidney: Clinicopathology and prognosis [J]. Journal of Peking University (Health Sciences), 2023, 55(2): 276-282.
[9] Quan ZHANG,Hai-feng SONG,Bing-lei MA,Zhe-nan ZHANG,Chao-hui ZHOU,Ao-lin LI,Jun LIU,Lei LIANG,Shi-yu ZHU,Qian ZHANG. Pre-operative prognostic nutritional index as a predictive factor for prognosis in non-metastatic renal cell carcinoma treated with surgery [J]. Journal of Peking University (Health Sciences), 2023, 55(1): 149-155.
[10] 利群 周,纯如 徐. [J]. Journal of Peking University (Health Sciences), 2022, 54(4): 587-591.
[11] 鑫 周,文智 李. [J]. Journal of Peking University (Health Sciences), 2022, 54(4): 595-598.
[12] Er-shu BO,Peng HONG,Yu ZHANG,Shao-hui DENG,Li-yuan GE,Min LU,Nan LI,Lu-lin MA,Shu-dong ZHANG. Clinicopathological features and prognostic analysis of papillary renal cell carcinoma [J]. Journal of Peking University (Health Sciences), 2022, 54(4): 615-620.
[13] Min QIU,Yan-yan LIAN,Min LU,Bin-shuai WANG,Xiao-jun TIAN,Jian LU,Cheng LIU,Shu-dong ZHANG,Min JIANG,Lu-lin MA. Treatment and prognosis of multiple primary malignant neoplasms complicated with renal cell carcinoma [J]. Journal of Peking University (Health Sciences), 2022, 54(4): 680-685.
[14] Yu TIAN,Xiao-yue CHENG,Hui-ying HE,Guo-liang WANG,Lu-lin MA. Clinical and pathological features of renal cell carcinoma with urinary tract tumor thrombus: 6 cases report and literature review [J]. Journal of Peking University (Health Sciences), 2021, 53(5): 928-932.
[15] YU Yan-fei,HE Shi-ming,WU Yu-cai,XIONG Sheng-wei,SHEN Qi,LI Yan-yan,YANG Feng,HE Qun,LI Xue-song. Clinicopathological features and prognosis of fumarate hydratase deficient renal cell carcinoma [J]. Journal of Peking University (Health Sciences), 2021, 53(4): 640-646.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright © Journal of Peking University (Health Sciences), All Rights Reserved.
Powered by Beijing Magtech Co. Ltd